Ilya Pharma AB

Developing the next-generation
biological drugs for treating wounds
in skin and mucosa

In press

2017-04-26

  Professor Mia Phillipson in "Secret lives of cells" from Wallenbergstiftelsen

Mia Phillipson describes her research of behavior on immune cells in the body in a production from Wallenbergstiftelserna. Enjoy! Discoveries in Professor Phillipson laboratory have led to the design of the drug candidates developed by ILYA Pharma and also that we now know the mechanism how wound healing is accelerated with our treatment.


Next

Ilya Pharma

Ilya Pharma, an innovative Swedish pharmaceutical company, develops drug candidates for PoC in clinical phase I and II from its technology platform of lactic acid bacteria expressing different human therapeutic proteins.

Board of Directors

Next

Technology

Human therapeutic proteins are delivered on site in wounds by living lactic acid bacteria acting like small bioreactors. This is a very cost-effective way to deliver biological drugs.

We have a freeze-dried formulation with good stability. The lactic acid bacteria are revived immediately prior use by addition of a small volume of water.

Next

Science

The innovation stems from world-leading medical research in immunophysiology and microbiology at Uppsala University and the Swedish University of Agricultural Sciences. The treatments target the function of tissue-resident immune cells and the mechanism of accelerated healing is defined by us.

Next

Unmet clinical need

The unmet clinical need targeted by Ilya Pharma is healing both acute and chronic wounds,  especially problematic for people with diabetes. Indications in the gastrointestinal tract such as irritable bowel disease are also being explored.

There is much room for improvement in wound care and the innovative technology of Ilya Pharma offers a more efficient and very cost effective treatment compared to treatment with conventional biological drugs, expected to enter the wound care market.

Next

Investor relations

Ilya Pharma now invites experienced industrial partners and venture capitalists with know-how in drug development as new owners to finance activities associated with the planned Phase I clinical trial. 

Contact

Next

Board of directors

 

Evelina Vågesjö, CEO

Co-founder, PhD in physiology. Developed methods to steer immune cell function to accelerate healing and blood flow regulation in the lab of Professor Mia Phillipson. Also delineated the mechanism of action during this time. BSc in Management Accounting and will complete an MBA during 2017.

Mia Phillipson, CSO

Co-founder, facilitator and Professor in Physiology at Uppsala University. Internationally recognized expert in physiology and immunology. Multiple discoveries in Professor Phillipson’s lab have led to clinical initiatives.

Stefan Roos, CTO

Co-founder and Ass. Professor in Microbiology at the Swedish University of Agricultural Sciences. Has long research experience in microbiology and bacteria-host interactions. Special expertise in lactic acid bacteria biology, technology transfer and the commercialization of probiotic innovations.

Göran Beijer, Chairman of the Board

Co-founder with long experience from leading positions in the biotechnology and life-science industries. Formerly CEO ONCOlog AB and NOLabs AB. Has held executive positions at Tamro, Astra Zeneca and Pharmacia. Works with business development and organization.

Next

Contact Us

info@ilyapharma.se

Ilya Pharma AB, Uppsala, Sweden

Evelina Vågesjö, CEO
+46 (0)70 636 64 94